Pharmacology

The Therapeutic Power of Monoclonal Antibody Therapy

Darren Berger DVM, DACVD, Assistant Professor College of Veterinary Medicine, Iowa State University, Ames, Iowa

Darren Berger is assistant professor of dermatology at Iowa State University’s College of Veterinary Medicine. Dr. Berger’s research interests include clinical pharmacology and the clinical management of canine atopic dermatitis and equine hypersensitivity disorders. A graduate of Iowa State University, he worked as a small animal general practitioner before completing a dermatology residency with Dermatology for Animals in Gilbert, Arizona.

The Therapeutic Power of Monoclonal Antibody Therapy
A UNIQUE APPROACH Lokivetmab targets and neutralizes interleukin-31, a key itch-inducing cytokine in canine atopic dermatitis, without the side effects that can be caused by steroids. Photo Credit: shutterstock.com/Dasha Iunskaya.
  • 1
  •  
  •  
  •  
  •  
  •  
  •  
    1
    Share

Although biotherapeutics have been used in human medicine for more than 30 years, they are still relatively new in veterinary medicine.1 Recent advances in the veterinary arena include updated labeling and industry acquisition and collaboration to develop new biologic agents. This article reviews biologic therapy as it relates specifically to monoclonal antibodies (mAbs) and covers the only fully licensed and commercially available product, lokivetmab (CYTOPOINT™), which is made by Zoetis.

PRINCIPLES OF BIOTHERAPY

Biotherapy differs from traditional pharmacotherapy in that it mimics the body’s normal immune response to treat disease or protect against adverse events.2 Biologic agents are commonly categorized into 3 groups:

  1. Peptides and small proteins (hormones and cytokines)
  2. Nonimmune proteins (replacement enzymes and blood factors)
  3. Therapeutic antibodies and Fc receptor–like proteins

The major advantages of biotherapeutic agents over traditional drugs are the agents’ specificity, which facilitates precise action (ideally with minimal unintended effects), and their long half-lives, which allow infrequent dosing.1

In human medicine, mAbs represent the area of biotherapy that offers the greatest array of potential therapies. This is also the therapeutic arena most likely to see peak growth in products brought to the veterinary marketplace for clinical use in treating arthritis, autoimmune disease, allergic conditions, infectious disease, and oncologic disorders.2

MONOCLONAL ANTIBODIES

Production

mAbs are essentially identical to naturally occurring antibodies produced and secreted by plasma cells in the body. However, in a normal immune response to stimulation by an infectious agent or disease, numerous plasma cells produce thousands of antibodies that recognize multiple epitopes on a particular antigen. mAbs arise from a single plasma cell line and recognize the same target region on an antigen.

Production of mAbs was historically accomplished by immunizing mice, isolating the desired B cells, and fusing these cells with an immortal myeloma cell line (the hybridoma technique).3 However, when these murine antibodies were injected into nonmouse subjects, they stimulated significant undesired immune reactions. To resolve this problem, genetic engineering and recombinant DNA techniques have been developed, and speciated (humanized, caninized, or felinized) mAbs that are greater than 90% similar to those of the target species’ composition can now be created.3,4 This level of speciation limits the use of the products to only the labeled species but also decreases the risk of adverse effects.

As of September 2018, the label indication is that lokivetmab has been shown to be effective for the treatment of allergic dermatitis and atopic dermatitis in dogs.

Mechanism of Action

Therapeutic mAbs exert their biologic effect predominantly via one of three mechanisms. The first is through the binding or “soaking up” of soluble extracellular targets (i.e., cytokines) before these targets arrive at a cellular receptor.2 This action prevents the target molecules from activating cellular receptors and is the primary mechanism by which lokivetmab exerts its effect.

The second mechanism is to simply bind a target receptor on the cell surface and block activation of signal transduction; mAbs that act through this pathway are classified as antagonistic.2 Many currently approved human products act through this mechanism.2

The third mechanism is to bind to an infectious agent or cancer cell and either activate cell lysis (via complement-dependent cytotoxicity or antibody-dependent cell-mediated cytotoxicity) or enhance clearance of the foreign agent by antibody-dependent phagocytosis.1,2 The backbone or immunoglobulin (Ig) isotype also affects the specific mechanism of action and half-life of an individual mAb.5

Like any protein, mAbs undergo denaturation and proteolytic enzymatic breakdown in the stomach if given orally. Thus, all therapeutic mAbs are administered by intravenous, subcutaneous, or intramuscular injection. Once injected, they have long half-lives similar to those of naturally produced antibodies (roughly 20 days).2

Unlike traditional drugs, mAbs do not need to undergo biotransformation so that they can be inactivated or excreted from the body; rather, as biologic agents that mimic normal physiologic products, they are inactivated through pathways similar to that of the natural product. mAbs undergo intracellular catabolism within the lysosome, where they are broken down to amino acids that can either be recycled for the synthesis of new proteins or be renally excreted. This inactivation pathway provides mAbs a tremendous advantage over traditional drugs in that they are unlikely to result in adverse drug–drug interactions when administered to patients concurrently receiving other medications.

Safety

As with anything new, biotherapy carries with it concern about the unknown. Many practitioners worry about a wide array of potential adverse events from mAb therapy, most of which are unlikely, as mAbs are very target specific and have unique metabolic aspects. Because mAbs do not have intracellular activity, it is easier to predict adverse events before clinical trials, based on the anticipated blockade of the target, and it is a generally accepted concept that mAbs tend to be a safer form of treatment than traditional drugs. This improved risk–benefit ratio is grounded by the fact that the likelihood of a mAb reaching the market is roughly 4 times greater than that of a newly developed pharmacologic agent.1

The overall safety of any particular mAb is largely determined by the mAb’s target and level of speciation. Adverse events that have been encountered with therapeutic mAbs in human medicine are listed in BOX 1; these events are, for the most part, predictable based on the mechanism and target of the specific product.

BOX 1 Adverse Events Observed in Human Medicine With mAb Therapy1,6
  • Injection site discomfort
  • Lethargy
  • Fever
  • Gastrointestinal upset
  • Production of anti-drug antibodies
  • Anaphylaxis
  • Reactivation of infectious diseases
  • Thrombocytopenia
  • Leukopenia
  • Hypothyroidism
  • Pulmonary events
  • Autoimmune disease
  • Neoplasia (tumor necrosis factor-α specific products)
  • Pruritus
  • Erythema and rash
  • Cardiotoxicity
  • Tumor lysis syndrome
  • Cytokine release syndrome

Lokivetmab

To date, several mAbs have received conditional or full license approval. They include biologics for cancer therapy (blontuvetmab [Blontress®] and tamtuvetmab [Tactress®]) (aratana.com), osteoarthritis (ranevetmab and frunevetmab), and canine allergic dermatitis (lokivetmab). However, at this time, the only fully licensed commercially available product is lokivetmab.

Lokivetmab is a caninized anti–interleukin-31 (IL-31) mAb that works by neutralizing soluble IL-31 produced predominantly by lymphocytes. It was developed after IL-31 was shown to play a role in development of canine pruritus.7 IL-31’s potential role in the development of pruritus associated with atopic dermatitis has been further substantiated by more recent studies.8,9

Indication and Use

Lokivetmab is approved and licensed through the U.S. Department of Agriculture. The original label indication was to aid in the reduction of clinical signs associated with atopic dermatitis. As of September 2018, the label indication is that lokivetmab has been shown to be effective for the treatment of allergic dermatitis and atopic dermatitis in dogs.

Lokivetmab is provided in 1-mL sterile, ready-to-use vials (10, 20, 30, or 40 mg/mL). Individual vials are meant for single use and should be administered to a patient in their entirety via subcutaneous injection. The current labeled target dose is 2 mg/kg, which can be repeated every 4 to 8 weeks as needed.

Clinical Trials

Since lokivetmab’s release, several published studies and research abstracts have assessed its clinical efficacy and safety in dogs. The first study was a dose-determination study using client-owned dogs to assess efficacy and safety of a single subcutaneous injection over a 56-day period.10 In this study, dogs were randomly assigned to receive a dose of lokivetmab (0.125, 0.5, or 2 mg/kg) or placebo. Efficacy was evaluated by the clinician and the owner using objective scales. The study showed that clinical parameters were improved at the 2 higher doses compared with placebo and that the level and duration of response correlated with the dose given. In addition, pharmacokinetic data from this study revealed that the half-life for lokivetmab was 16 days, with peak serum concentration reached at 9.8 days after administration. Safety data generated in this clinical trial revealed no hypersensitivity-related reactions to the single injection immediately after dosing, no evidence of treatment-induced immunogenicity, and no specific safety concerns associated with treatment.10

A second study provided additional safety data from canine patients with atopic dermatitis receiving 2 doses of lokivetmab (1.0 to 3.3 mg/kg) compared with placebo.11 This study enrolled 245 dogs, and 2 injections were given 28 days apart. Adverse events observed in greater than 2% of participants included secondary skin or ear infections, pruritus, gastrointestinal (GI) upset (anorexia, vomiting, and diarrhea), and lethargy. Both treatment groups experienced GI upset and lethargy at a similar rate, which resolved spontaneously or with supportive care; no immediate hypersensitivity or injection site reactions were reported. However, 2.5% of lokivetmab-treated dogs developed treatment-induced immunogenicity. No adverse interactions with concomitant medications were observed in this study.11

A third investigation evaluated the safety and efficacy of lokivetmab compared with cyclosporine over a 3-month period, then followed 81 dogs for an additional 6 months as part of a continuation study.12 Overall, lokivetmab-treated patients compared favorably with those treated with cyclosporine. No significant differences between groups were appreciated in measured clinical outcome parameters. The continuation phase demonstrated continued efficacy, with 76.3% of animals assessed to have a normal level of pruritus after the ninth month of treatment. This study had safety results similar to those of the first 2 clinical trials, with GI upset occurring significantly less frequently in dogs treated with lokivetmab than in those treated with cyclosporine. No hypersensitivity reactions or immediate post-dosing injection site reactions were appreciated during the 9-month study. Treatment-induced immunogenicity was seen in 2% of dogs during the initial 3 months but in no new dogs during the continuation phase.12

The final published report at this time is a retrospective study that evaluated the experiences of dogs treated with lokivetmab over a 1-year period at a dermatology specialty hospital.13 Treatment with lokivetmab improved pruritus scores in 87.8% of dogs, with 77% of dogs experiencing >50% reduction in pruritus. There was no association of improvement with the dosage and response, but a trend was observed that larger dogs were more likely to be classified as treatment successes, as defined by reduction in pruritus scores. The study evaluated speed of onset and found that almost 96% of dogs responded within the first 72 hours after administration, with more than half (55.9%) experiencing improvement by 24 hours. Additionally, dogs with pruritus considered “severe” or “very severe” before treatment were more likely to be classified as treatment successes. Of note, 71.4% of dogs that had an inadequate response to oclacitinib, an oral JAK inhibitor, were considered treatment successes with lokivetmab.13 Adverse events were reported in 11 of 132 dogs (8.3%) treated with lokivetmab; the most common adverse effect reported was lethargy within 72 hours of receiving the injection (8 of 11 patients).13

Conclusion

Taken together, the clinical studies show that lokivetmab appears to be a safe and effective treatment option for dogs with allergic dermatitis. In addition, lokivetmab offers several advantages over traditional drugs (cyclosporine, oclacitinib, and glucocorticoids) used in the management of allergic dogs; namely, it can be given to dogs of all ages, with any concomitant medication, and with any concurrent medical condition. This therapy offers some exciting new opportunities in treating dogs with allergic dermatitis.

References

  1. Hansel TT, Kropshofer, Singer T, et al. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 2010;9:325-338.
  2. Olivry T, Bainbridge G. Clinical notes: Advances in veterinary medicine: therapeutic monoclonal antibodies for companion animals. Clinicians Brief 2015;13:76-79.
  3. Enomoto M, Mantyh PW, Murrell J, et al. Anti-nerve growth factor monoclonal antibodies for the control of pain in dogs and cats. Vet Rec 2019;184(1):23.
  4. Moyaert H, Van Brussel L, Borowski S, et al. A blinded, randomized clinical trial evaluating the efficacy and safety of lokivetmab compared to ciclosporin in client-owned dogs with atopic dermatitis. Vet Dermatol 2017;28:593-e145.
  5. Bergeron LM, McCandless EE, Dunham S, et al. Comparative functional characterization of canine IgG subclasses. Vet Immunol Immunopathol 2014;157:31-41.
  6. Baldo BA. Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses. Oncoimmunology 2013;2(10):1-15.
  7. Gonzales AJ, Humphrey WR, Messamore JE, et al. Interleukin-31: its role in canine pruritus and naturally occurring canine atopic dermatitis. Vet Dermatol 2013;24:48-e12.
  8. Marsella R, Ahrens K, Sanford R. Investigation of the correlation of serum IL-31 with severity of dermatitis in an experimental model of canine atopic dermatitis using beagle dogs. Vet Dermatol 2018;29:69-e28.
  9. Messamore JE. An ultrasensitive single molecule array (Simoa) for the detection of IL-31 in canine serum shows differential levels in dogs affected with atopic dermatitis compared to healthy animals. Vet Dermatol 2017;28:546.
  10. Michels GM, Ramsey DS, Walsh KF, et al. A blinded, randomized, placebo-controlled, dose determination trial of lokivetmab (ZTS-00103289), a caninized, anti-canine IL-31 monoclonal antibody in client owned dogs with atopic dermatitis. Vet Dermatol 2016;27:478-e129.
  11. Michels GM, Walsh KF, Kryda KA, et al. A blinded, randomized, placebo-controlled trial of the safety of lokivetmab (ZTS-00103289), a caninized anti-canine IL-31 monoclonal antibody in client-owned dogs with atopic dermatitis. Vet Dermatol 2016;27:505-e136.
  12. Moyaert H, Van Brussel L, Borowshi S, et al. A blinded, randomized clinical trial evaluating efficacy and safety of lokivetmab compared to ciclosporin in client-owned dogs with atopic dermatitis. Vet Dermatol 2017;28:593-e145.
  13. Souza CP, Rosychuck RA, Contreras ET, et al. A retrospective analysis of the use of lokivetmab in the management of allergic pruritus in a referral population of 135 dogs in the western USA. Vet Dermatol 2018;29:489-e164.

DMCA.com Protection Status
[gravityform id="6" title="false" description="false"]
<div class='gf_browser_unknown gform_wrapper' id='gform_wrapper_6' style='display:none'><form method='post' enctype='multipart/form-data' id='gform_6' action='/the-therapeutic-power-of-monoclonal-antibody-therapy/'> <div class='gform_body'><ul id='gform_fields_6' class='gform_fields top_label form_sublabel_below description_below'><li id='field_6_1' class='gfield gfield_contains_required field_sublabel_below field_description_below gfield_visibility_visible' ><label class='gfield_label gfield_label_before_complex' >Name<span class='gfield_required'>*</span></label><div class='ginput_complex ginput_container no_prefix has_first_name no_middle_name has_last_name no_suffix gf_name_has_2 ginput_container_name' id='input_6_1'> <span id='input_6_1_3_container' class='name_first' > <input type='text' name='input_1.3' id='input_6_1_3' value='' aria-label='First name' aria-required="true" aria-invalid="false" /> <label for='input_6_1_3' >First</label> </span> <span id='input_6_1_6_container' class='name_last' > <input type='text' name='input_1.6' id='input_6_1_6' value='' aria-label='Last name' aria-required="true" aria-invalid="false" /> <label for='input_6_1_6' >Last</label> </span> </div></li><li id='field_6_2' class='gfield gfield_contains_required field_sublabel_below field_description_below gfield_visibility_visible' ><label class='gfield_label' for='input_6_2' >Email<span class='gfield_required'>*</span></label><div class='ginput_container ginput_container_email'> <input name='input_2' id='input_6_2' type='text' value='' class='medium' aria-required="true" aria-invalid="false" /> </div></li><li id='field_6_7' class='gfield gfield_contains_required field_sublabel_below field_description_below gfield_visibility_visible' ><label class='gfield_label' for='input_6_7' >Profession / Role<span class='gfield_required'>*</span></label><div class='ginput_container ginput_container_select'><select name='input_7' id='input_6_7' class='medium gfield_select' aria-required="true" aria-invalid="false"><option value='Veterinarian' >Veterinarian</option><option value='Veterinary Nurse / Technician' >Veterinary Nurse / Technician</option><option value='Practice Manager / Veterinary Assistant / Support Staff' >Practice Manager / Veterinary Assistant / Support Staff</option><option value='Student (Veterinarian or Veterinary Nurse)' >Student (Veterinarian or Veterinary Nurse)</option><option value='Other' >Other</option></select></div></li><li id='field_6_20' class='gfield gfield_html gfield_html_formatted gfield_no_follows_desc field_sublabel_below field_description_below gfield_visibility_visible' ><br></li><li id='field_6_15' class='gfield field_sublabel_below field_description_above gfield_visibility_visible' ><label class='gfield_label' >Inbox Preferences</label><div class='gfield_description' id='gfield_description_6_15'>Customize your inbox by selecting the areas you are most interested in. </div><div class='ginput_container ginput_container_checkbox'><ul class='gfield_checkbox' id='input_6_15'><li class='gchoice_6_15_1'> <input name='input_15.1' type='checkbox' value='NAVC Better Care Weekly&lt;br&gt;&lt;div style=&quot;font-size: 12px;color: #808080&quot;&gt;A weekly roundup of the new and noteworthy innovations and educational opportunities in the veterinary industry.&lt;/div&gt;' checked='checked' id='choice_6_15_1' /> <label for='choice_6_15_1' id='label_6_15_1'>NAVC Better Care Weekly<br><div style="font-size: 12px; color: #808080;">A weekly roundup of the new and noteworthy innovations and educational opportunities in the veterinary industry.</div></label> </li><li class='gchoice_6_15_2'> <input name='input_15.2' type='checkbox' value='Today&#039;s Veterinary Business eNewsletter&lt;br&gt;&lt;div style=&quot;font-size: 12px;color: #808080&quot;&gt;Covers topics relating to practice management, financial metrics, marketing, retailing and merchandising, and industry news.&lt;/div&gt;' id='choice_6_15_2' /> <label for='choice_6_15_2' id='label_6_15_2'>Today's Veterinary Business eNewsletter<br><div style="font-size: 12px; color: #808080;">Covers topics relating to practice management, financial metrics, marketing, retailing and merchandising, and industry news.</div></label> </li><li class='gchoice_6_15_3'> <input name='input_15.3' type='checkbox' value='Today&#039;s Veterinary Nurse eNewsletter&lt;br&gt;&lt;div style=&quot;font-size: 12px;color: #808080&quot;&gt;Provides practical, peer-reviewed companion animal educational CE for veterinary nurses, technicians and assistants.&lt;/div&gt;' id='choice_6_15_3' /> <label for='choice_6_15_3' id='label_6_15_3'>Today's Veterinary Nurse eNewsletter<br><div style="font-size: 12px; color: #808080;">Provides practical, peer-reviewed companion animal educational CE for veterinary nurses, technicians and assistants.</div></label> </li><li class='gchoice_6_15_4'> <input name='input_15.4' type='checkbox' value='Today&#039;s Veterinary Practice eNewsletter&lt;br&gt;&lt;div style=&quot;font-size: 12px;color: #808080&quot;&gt;Provides practical, peer-reviewed articles focused on the latest diagnostic and treatment techniques to enhance your knowledge and confidence.&lt;/div&gt;' id='choice_6_15_4' /> <label for='choice_6_15_4' id='label_6_15_4'>Today's Veterinary Practice eNewsletter<br><div style="font-size: 12px; color: #808080;">Provides practical, peer-reviewed articles focused on the latest diagnostic and treatment techniques to enhance your knowledge and confidence.</div></label> </li><li class='gchoice_6_15_5'> <input name='input_15.5' type='checkbox' value='VetFolio eNewsletter&lt;br&gt;&lt;div style=&quot;font-size: 12px;color: #808080&quot;&gt;Discover online CE resources offered in a variety of formats including videos, podcasts, webinars and more.&lt;/div&gt;' id='choice_6_15_5' /> <label for='choice_6_15_5' id='label_6_15_5'>VetFolio eNewsletter<br><div style="font-size: 12px; color: #808080;">Discover online CE resources offered in a variety of formats including videos, podcasts, webinars and more.</div></label> </li><li class='gchoice_6_15_6'> <input name='input_15.6' type='checkbox' value='Partner Emails&lt;br&gt;&lt;div style=&quot;font-size: 12px;color: #808080&quot;&gt;Exclusive deals and information from our partners.&lt;/div&gt;' id='choice_6_15_6' /> <label for='choice_6_15_6' id='label_6_15_6'>Partner Emails<br><div style="font-size: 12px; color: #808080;">Exclusive deals and information from our partners.</div></label> </li></ul></div></li><li id='field_6_19' class='gfield gfield_html gfield_html_formatted field_sublabel_below field_description_below gfield_visibility_visible' ><br></li><li id='field_6_22' class='gfield field_sublabel_below field_description_below gfield_visibility_visible' ><label class='gfield_label' >Do you want to be added to our postal mailing list?</label><div class='ginput_container ginput_container_checkbox'><ul class='gfield_checkbox' id='input_6_22'><li class='gchoice_6_22_1'> <input name='input_22.1' type='checkbox' value='Yes, I love mail!' id='choice_6_22_1' /> <label for='choice_6_22_1' id='label_6_22_1'>Yes, I love mail!</label> </li><li class='gchoice_6_22_2'> <input name='input_22.2' type='checkbox' value='No thank you.' id='choice_6_22_2' /> <label for='choice_6_22_2' id='label_6_22_2'>No thank you.</label> </li></ul></div></li><li id='field_6_10' class='gfield gfield_contains_required field_sublabel_below field_description_below gfield_visibility_visible' ><label class='gfield_label gfield_label_before_complex' >Please provide your mailing address below.<span class='gfield_required'>*</span></label> <div class='ginput_complex ginput_container has_street has_street2 has_city has_state has_zip has_country ginput_container_address' id='input_6_10' > <span class='ginput_full address_line_1' id='input_6_10_1_container' > <input type='text' name='input_10.1' id='input_6_10_1' value='' aria-required="true"/> <label for='input_6_10_1' id='input_6_10_1_label' >Street Address</label> </span><span class='ginput_full address_line_2' id='input_6_10_2_container' > <input type='text' name='input_10.2' id='input_6_10_2' value='' /> <label for='input_6_10_2' id='input_6_10_2_label' >Address Line 2</label> </span><span class='ginput_left address_city' id='input_6_10_3_container' > <input type='text' name='input_10.3' id='input_6_10_3' value='' aria-required="true"/> <label for='input_6_10_3' id='input_6_10_3_label' >City</label> </span><span class='ginput_right address_state' id='input_6_10_4_container' > <input type='text' name='input_10.4' id='input_6_10_4' value='' aria-required="true"/> <label for='input_6_10_4' id='input_6_10_4_label' >State / Province / Region</label> </span><span class='ginput_left address_zip' id='input_6_10_5_container' > <input type='text' name='input_10.5' id='input_6_10_5' value='' aria-required="true"/> <label for='input_6_10_5' id='input_6_10_5_label' >ZIP / Postal Code</label> </span><span class='ginput_right address_country' id='input_6_10_6_container' > <select name='input_10.6' id='input_6_10_6' aria-required="true"><option value='' selected='selected'></option><option value='Afghanistan' >Afghanistan</option><option value='Åland Islands' >Åland Islands</option><option value='Albania' >Albania</option><option value='Algeria' >Algeria</option><option value='American Samoa' >American Samoa</option><option value='Andorra' >Andorra</option><option value='Angola' >Angola</option><option value='Anguilla' >Anguilla</option><option value='Antarctica' >Antarctica</option><option value='Antigua and Barbuda' >Antigua and Barbuda</option><option value='Argentina' >Argentina</option><option value='Armenia' >Armenia</option><option value='Aruba' >Aruba</option><option value='Australia' >Australia</option><option value='Austria' >Austria</option><option value='Azerbaijan' >Azerbaijan</option><option value='Bahamas' >Bahamas</option><option value='Bahrain' >Bahrain</option><option value='Bangladesh' >Bangladesh</option><option value='Barbados' >Barbados</option><option value='Belarus' >Belarus</option><option value='Belgium' >Belgium</option><option value='Belize' >Belize</option><option value='Benin' >Benin</option><option value='Bermuda' >Bermuda</option><option value='Bhutan' >Bhutan</option><option value='Bolivia' >Bolivia</option><option value='Bonaire, Sint Eustatius and Saba' >Bonaire, Sint Eustatius and Saba</option><option value='Bosnia and Herzegovina' >Bosnia and Herzegovina</option><option value='Botswana' >Botswana</option><option value='Bouvet Island' >Bouvet Island</option><option value='Brazil' >Brazil</option><option value='British Indian Ocean Territory' >British Indian Ocean Territory</option><option value='Brunei Darussalam' >Brunei Darussalam</option><option value='Bulgaria' >Bulgaria</option><option value='Burkina Faso' >Burkina Faso</option><option value='Burundi' >Burundi</option><option value='Cambodia' >Cambodia</option><option value='Cameroon' >Cameroon</option><option value='Canada' >Canada</option><option value='Cape Verde' >Cape Verde</option><option value='Cayman Islands' >Cayman Islands</option><option value='Central African Republic' >Central African Republic</option><option value='Chad' >Chad</option><option value='Chile' >Chile</option><option value='China' >China</option><option value='Christmas Island' >Christmas Island</option><option value='Cocos Islands' >Cocos Islands</option><option value='Colombia' >Colombia</option><option value='Comoros' >Comoros</option><option value='Congo, Democratic Republic of the' >Congo, Democratic Republic of the</option><option value='Congo, Republic of the' >Congo, Republic of the</option><option value='Cook Islands' >Cook Islands</option><option value='Costa Rica' >Costa Rica</option><option value='Côte d&#039;Ivoire' >Côte d&#039;Ivoire</option><option value='Croatia' >Croatia</option><option value='Cuba' >Cuba</option><option value='Curaçao' >Curaçao</option><option value='Cyprus' >Cyprus</option><option value='Czech Republic' >Czech Republic</option><option value='Denmark' >Denmark</option><option value='Djibouti' >Djibouti</option><option value='Dominica' >Dominica</option><option value='Dominican Republic' >Dominican Republic</option><option value='Ecuador' >Ecuador</option><option value='Egypt' >Egypt</option><option value='El Salvador' >El Salvador</option><option value='Equatorial Guinea' >Equatorial Guinea</option><option value='Eritrea' >Eritrea</option><option value='Estonia' >Estonia</option><option value='Eswatini (Swaziland)' >Eswatini (Swaziland)</option><option value='Ethiopia' >Ethiopia</option><option value='Falkland Islands' >Falkland Islands</option><option value='Faroe Islands' >Faroe Islands</option><option value='Fiji' >Fiji</option><option value='Finland' >Finland</option><option value='France' >France</option><option value='French Guiana' >French Guiana</option><option value='French Polynesia' >French Polynesia</option><option value='French Southern Territories' >French Southern Territories</option><option value='Gabon' >Gabon</option><option value='Gambia' >Gambia</option><option value='Georgia' >Georgia</option><option value='Germany' >Germany</option><option value='Ghana' >Ghana</option><option value='Gibraltar' >Gibraltar</option><option value='Greece' >Greece</option><option value='Greenland' >Greenland</option><option value='Grenada' >Grenada</option><option value='Guadeloupe' >Guadeloupe</option><option value='Guam' >Guam</option><option value='Guatemala' >Guatemala</option><option value='Guernsey' >Guernsey</option><option value='Guinea' >Guinea</option><option value='Guinea-Bissau' >Guinea-Bissau</option><option value='Guyana' >Guyana</option><option value='Haiti' >Haiti</option><option value='Heard and McDonald Islands' >Heard and McDonald Islands</option><option value='Holy See' >Holy See</option><option value='Honduras' >Honduras</option><option value='Hong Kong' >Hong Kong</option><option value='Hungary' >Hungary</option><option value='Iceland' >Iceland</option><option value='India' >India</option><option value='Indonesia' >Indonesia</option><option value='Iran' >Iran</option><option value='Iraq' >Iraq</option><option value='Ireland' >Ireland</option><option value='Isle of Man' >Isle of Man</option><option value='Israel' >Israel</option><option value='Italy' >Italy</option><option value='Jamaica' >Jamaica</option><option value='Japan' >Japan</option><option value='Jersey' >Jersey</option><option value='Jordan' >Jordan</option><option value='Kazakhstan' >Kazakhstan</option><option value='Kenya' >Kenya</option><option value='Kiribati' >Kiribati</option><option value='Kuwait' >Kuwait</option><option value='Kyrgyzstan' >Kyrgyzstan</option><option value='Lao People&#039;s Democratic Republic' >Lao People&#039;s Democratic Republic</option><option value='Latvia' >Latvia</option><option value='Lebanon' >Lebanon</option><option value='Lesotho' >Lesotho</option><option value='Liberia' >Liberia</option><option value='Libya' >Libya</option><option value='Liechtenstein' >Liechtenstein</option><option value='Lithuania' >Lithuania</option><option value='Luxembourg' >Luxembourg</option><option value='Macau' >Macau</option><option value='Macedonia' >Macedonia</option><option value='Madagascar' >Madagascar</option><option value='Malawi' >Malawi</option><option value='Malaysia' >Malaysia</option><option value='Maldives' >Maldives</option><option value='Mali' >Mali</option><option value='Malta' >Malta</option><option value='Marshall Islands' >Marshall Islands</option><option value='Martinique' >Martinique</option><option value='Mauritania' >Mauritania</option><option value='Mauritius' >Mauritius</option><option value='Mayotte' >Mayotte</option><option value='Mexico' >Mexico</option><option value='Micronesia' >Micronesia</option><option value='Moldova' >Moldova</option><option value='Monaco' >Monaco</option><option value='Mongolia' >Mongolia</option><option value='Montenegro' >Montenegro</option><option value='Montserrat' >Montserrat</option><option value='Morocco' >Morocco</option><option value='Mozambique' >Mozambique</option><option value='Myanmar' >Myanmar</option><option value='Namibia' >Namibia</option><option value='Nauru' >Nauru</option><option value='Nepal' >Nepal</option><option value='Netherlands' >Netherlands</option><option value='New Caledonia' >New Caledonia</option><option value='New Zealand' >New Zealand</option><option value='Nicaragua' >Nicaragua</option><option value='Niger' >Niger</option><option value='Nigeria' >Nigeria</option><option value='Niue' >Niue</option><option value='Norfolk Island' >Norfolk Island</option><option value='North Korea' >North Korea</option><option value='Northern Mariana Islands' >Northern Mariana Islands</option><option value='Norway' >Norway</option><option value='Oman' >Oman</option><option value='Pakistan' >Pakistan</option><option value='Palau' >Palau</option><option value='Palestine, State of' >Palestine, State of</option><option value='Panama' >Panama</option><option value='Papua New Guinea' >Papua New Guinea</option><option value='Paraguay' >Paraguay</option><option value='Peru' >Peru</option><option value='Philippines' >Philippines</option><option value='Pitcairn' >Pitcairn</option><option value='Poland' >Poland</option><option value='Portugal' >Portugal</option><option value='Puerto Rico' >Puerto Rico</option><option value='Qatar' >Qatar</option><option value='Réunion' >Réunion</option><option value='Romania' >Romania</option><option value='Russia' >Russia</option><option value='Rwanda' >Rwanda</option><option value='Saint Barthélemy' >Saint Barthélemy</option><option value='Saint Helena' >Saint Helena</option><option value='Saint Kitts and Nevis' >Saint Kitts and Nevis</option><option value='Saint Lucia' >Saint Lucia</option><option value='Saint Martin' >Saint Martin</option><option value='Saint Pierre and Miquelon' >Saint Pierre and Miquelon</option><option value='Saint Vincent and the Grenadines' >Saint Vincent and the Grenadines</option><option value='Samoa' >Samoa</option><option value='San Marino' >San Marino</option><option value='Sao Tome and Principe' >Sao Tome and Principe</option><option value='Saudi Arabia' >Saudi Arabia</option><option value='Senegal' >Senegal</option><option value='Serbia' >Serbia</option><option value='Seychelles' >Seychelles</option><option value='Sierra Leone' >Sierra Leone</option><option value='Singapore' >Singapore</option><option value='Sint Maarten' >Sint Maarten</option><option value='Slovakia' >Slovakia</option><option value='Slovenia' >Slovenia</option><option value='Solomon Islands' >Solomon Islands</option><option value='Somalia' >Somalia</option><option value='South Africa' >South Africa</option><option value='South Georgia' >South Georgia</option><option value='South Korea' >South Korea</option><option value='South Sudan' >South Sudan</option><option value='Spain' >Spain</option><option value='Sri Lanka' >Sri Lanka</option><option value='Sudan' >Sudan</option><option value='Suriname' >Suriname</option><option value='Svalbard and Jan Mayen Islands' >Svalbard and Jan Mayen Islands</option><option value='Sweden' >Sweden</option><option value='Switzerland' >Switzerland</option><option value='Syria' >Syria</option><option value='Taiwan' >Taiwan</option><option value='Tajikistan' >Tajikistan</option><option value='Tanzania' >Tanzania</option><option value='Thailand' >Thailand</option><option value='Timor-Leste' >Timor-Leste</option><option value='Togo' >Togo</option><option value='Tokelau' >Tokelau</option><option value='Tonga' >Tonga</option><option value='Trinidad and Tobago' >Trinidad and Tobago</option><option value='Tunisia' >Tunisia</option><option value='Turkey' >Turkey</option><option value='Turkmenistan' >Turkmenistan</option><option value='Turks and Caicos Islands' >Turks and Caicos Islands</option><option value='Tuvalu' >Tuvalu</option><option value='Uganda' >Uganda</option><option value='Ukraine' >Ukraine</option><option value='United Arab Emirates' >United Arab Emirates</option><option value='United Kingdom' >United Kingdom</option><option value='United States' >United States</option><option value='Uruguay' >Uruguay</option><option value='US Minor Outlying Islands' >US Minor Outlying Islands</option><option value='Uzbekistan' >Uzbekistan</option><option value='Vanuatu' >Vanuatu</option><option value='Venezuela' >Venezuela</option><option value='Vietnam' >Vietnam</option><option value='Virgin Islands, British' >Virgin Islands, British</option><option value='Virgin Islands, U.S.' >Virgin Islands, U.S.</option><option value='Wallis and Futuna' >Wallis and Futuna</option><option value='Western Sahara' >Western Sahara</option><option value='Yemen' >Yemen</option><option value='Zambia' >Zambia</option><option value='Zimbabwe' >Zimbabwe</option></select> <label for='input_6_10_6' id='input_6_10_6_label' >Country</label> </span> <div class='gf_clear gf_clear_complex'></div> </div></li> </ul></div> <div class='gform_footer top_label'> <input type='submit' id='gform_submit_button_6' class='gform_button button' value='Sign Up' onclick='if(window["gf_submitting_6"]){return false;} window["gf_submitting_6"]=true; ' onkeypress='if( event.keyCode == 13 ){ if(window["gf_submitting_6"]){return false;} window["gf_submitting_6"]=true; jQuery("#gform_6").trigger("submit",[true]); }' /> <input type='hidden' class='gform_hidden' name='is_submit_6' value='1' /> <input type='hidden' class='gform_hidden' name='gform_submit' value='6' /> <input type='hidden' class='gform_hidden' name='gform_unique_id' value='' /> <input type='hidden' class='gform_hidden' name='state_6' value='WyJbXSIsIjNkNTNhNjhlOThlOGY4N2JlZWZiNTRmZDhlZDQ5OWI3Il0=' /> <input type='hidden' class='gform_hidden' name='gform_target_page_number_6' id='gform_target_page_number_6' value='0' /> <input type='hidden' class='gform_hidden' name='gform_source_page_number_6' id='gform_source_page_number_6' value='1' /> <input type='hidden' name='gform_field_values' value='' /> </div> </form> </div><script type='text/javascript'> jQuery(document).bind('gform_post_render', function(event, formId, currentPage){if(formId == 6) {gf_global["number_formats"][6] = {"1":{"price":false,"value":false},"2":{"price":false,"value":false},"7":{"price":false,"value":false},"20":{"price":false,"value":false},"15":{"price":false,"value":false},"19":{"price":false,"value":false},"22":{"price":false,"value":false},"10":{"price":false,"value":false}};if(window['jQuery']){if(!window['gf_form_conditional_logic'])window['gf_form_conditional_logic'] = new Array();window['gf_form_conditional_logic'][6] = { logic: { 10: {"field":{"actionType":"show","logicType":"any","rules":[{"fieldId":"22","operator":"is","value":"Yes, I love mail!"}]},"nextButton":null,"section":null} }, dependents: { 10: [10] }, animation: 1, defaults: {"1":{"1.2":"","1.3":"","1.4":"","1.6":"","1.8":""},"15":["choice_6_15_1"],"10":{"10.1":"","10.2":"","10.3":"","10.4":"","10.5":"","10.6":""}}, fields: {"1":[],"2":[],"7":[],"20":[],"15":[],"19":[],"22":[10],"10":[]} }; if(!window['gf_number_format'])window['gf_number_format'] = 'decimal_dot';jQuery(document).ready(function(){gf_apply_rules(6, [10], true);jQuery('#gform_wrapper_6').show();jQuery(document).trigger('gform_post_conditional_logic', [6, null, true]);} );} gformInitChosenFields('#input_6_7','No results matched');} } );jQuery(document).bind('gform_post_conditional_logic', function(event, formId, fields, isInit){gformInitChosenFields('#input_6_7','No results matched');} );</script><script type='text/javascript'> jQuery(document).ready(function(){jQuery(document).trigger('gform_post_render', [6, 1]) } ); </script>
MENU